Kidd, Sharon A.
https://orcid.org/0000-0002-7562-8682
Mayo Clinic
University of California, San Francisco
Citations 2
Newborn screening reduces survival disparities in SCID after stem cell transplant: A PIDTC report
Winestone, Lena E. , Logan, Brent R. , Liu, Xuerong , Williams, Olatundun , Dunn, Elizabeth A. , Thakar, Monica S. , Kidd, Sharon A. , Dorsey, Morna J. , O'Reilly, R, Kapoor, Neena , Kapadia, Malika , Jyonouchi, Soma , Chandra, Sharat , Chellapandian, Deepak , Chaudhury, Sonali , Chen, Karin , Rayes, Ahmad , Quigg, Troy C. , Teira, Pierre , Gillio, Alfred P. , Eissa, Hesham, Knutsen, Alan P., Aquino, Victor M. , Shereck, Evan , Lugt, Mark T. Vander , Rozmus, Jacob, Yu, Lolie C. , Shah, Ami J. , Joshi, Avni Y. , Buckley, Rebecca H. , Oved, Joseph H. , Azim, Hisham Abdel, Martinez, Caridad , Sullivan, Kathleen E. , Bleesing, Jack J., Madden, Lisa, Shenoy, Shalini , Seroogy, Christine M. , Rubin, Tamar N. , Licata, Jennifer, Andolina, Jeffrey R. , Burroughs, Lauri M. , Leiding, Jennifer W. , Marsh, Rebecca , Pai, Sung‐Yun , Torgerson, Troy R. , Heimall, Jennifer , Griffith, Linda M. , Puck, Jennifer M. , Dvorak, Christopher C. , Cowan, Morton J. , Liu, Xuerong , Mousallem, Talal , Dorsey, Morna J , O'Reilly, Richard J , Kapoor, Neena , Forbes Satter, Lisa R , Kapadia, Malika , Chandra, Sharat , Ebens, Christen L , Chellapandian, Deepakbabu , Chaudhury, Sonali , Chen, Karin , Dávila Saldaña, Blachy J , Rayes, Ahmad , Quigg, Troy C , Chandrakasan, Shanmuganathan , Bednarski, Jeffrey J , DeSantes, Kenneth B , Teira, Pierre , Gillio, Alfred P , Eissa, Hesham , Aquino, Victor M , Shereck, Evan B , Moore, Theodore Bruce , Caywood, Emi H , Vander Lugt, Mark T , Rozmus, Jacob , Broglie, Larisa A , Yu, Lolie C. , Shah, Ami J , Joshi, Avni Y , Buckley, Rebecca H , Dara, Jasmeen , Oved, Joseph H , Abdel Azim, Hisham , Martinez, Caridad , Prockop, Susan E , Sullivan, Kathleen E , Bleesing, Jack J , Keller, Michael D , Madden, Lisa M , Parikh, Suhag , Shenoy, Shalini , Seroogy, Christine M , Rubin, Tamar , Licata, Jennifer , Andolina, Jeffrey R , Kohn, Donald B , Burroughs, Lauri M , Leiding, Jennifer W , Marsh, Rebecca A , Notarangelo, Luigi D , Pai, Sung-Yun , Torgerson, Troy R , Pulsipher, Michael A. , Heimall, Jennifer , Cuvelier, Geoffrey D E , Griffith, Linda M , Puck, Jennifer M , Dvorak, Christopher C , Cowan, Morton J , Haddad, Elie , Winestone, Lena E , Satter, Lisa Forbes , Ebens, Christen L. , Saldaña, Blachy J. Dávila , Chandrakasan, Shanmuganathan , Knutsen, Alan P. , Broglie, Larisa , Dara, Jasmeen , Abdel‐Azim, Hisham , Prockop, Susan E. , Bleesing, Jack , Keller, Michael D. , Parikh, Suhag , Kohn, Donald B. , Cuvelier, Geoff D.E. , Haddad, Élie
Journal of Human Immunity | July 7, 2026 | Volume: 2 | Issue: 5 | Pages: No page available
Black race and Hispanic ethnicity are associated with higher mortality in severe combined immunodeficiency (SCID) following hematopoietic cell transplantation (HCT), though mechanisms remain unclear. We evaluated 796 children with SCID who received nonsibling HCT between 1982 and 2020 using data from the Primary Immune Deficiency Treatment Consortium. Overall survival for Black (aHR 2.47, 95%CI 1.64, 3.71) and Asian/Pacific Islander patients (aHR 1.82, 95%CI 1.00, 3.30) was significantly lower compared with non-Hispanic White patients, while Hispanic patients had lower event-free survival (aHR 1.83, 95%CI 1.27, 2.63) compared with non-Hispanic White patients. Even after adjusting for age and infection, Black patients with SCID had more than twofold hazard of death compared with non-Hispanic White patients. NBS was associated with earlier diagnosis, reduced infection at HCT, and elimination of survival disparities between Black and non-Hispanic White patients. These findings suggest that universal, system-level interventions such as NBS can mitigate disparities in outcomes for children with SCID.
Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD
Leiding, Jennifer W. , Arnold, Danielle E. , Parikh, Suhag , Logan, Brent R. , Marsh, Rebecca , Griffith, Linda M. , Wu, Ruizhe , Kidd, Sharon A. , Mallhi, Kanwaldeep , Chellapandian, Deepak , Lim, Stephanie Si , Grunebaum, Eyal , Falcone, Emilia Liana , Grossman, Debbi, Prasad, Vinod K. , Heimall, Jennifer , Burroughs, Lauri M. , Bleesing, Jack , Kapoor, Neena , Dara, Jasmeen , Williams, Olatundun , Kapadia, Malika, Oshrine, Benjamin , Rayes, Ahmad , Chong, Hey , Satter, Lisa Forbes , Martinez, Caridad , Lugt, Mark T. Vander , Yu, Lolie C. , Joshi, Avni Y. , Prockop, Susan E. , Aquino, Victor , Madden, Lisa, Milner, Jordan , Rangarajan, Hemalatha G. , Shah, Ami J. , Gillio, Alfred P. , Knutsen, Alan P. , Miller, Holly, Graham, Pamela, Bauchat, Andrea , Bunin, Nancy , Teira, Pierre , Petrović, Aleksandra , Chandra, Sharat , Abdel‐Azim, Hisham , Birbrayer, Olga, Cowan, Morton J. , Dvorak, Christopher C. , Pai, Sung‐Yun , Puck, Jennifer M. , Torgerson, Troy R. , Kang, Elizabeth M. , Si Lim, Stephanie J , Murguia-Favela, Luis , Prasad, Vinod K , Touzot, Fabien , Bednarski, Jeffrey J , Cuvelier, Geoffrey D E , Forbes Satter, Lisa R , Martinez, Caridad , Joshi, Avni, Prockop, Susan E , Dávila Saldaña, Blachy J , Broglie, Larisa A , Ebens, Christen L , Milner, Jordan , Rangarajan, Hemalatha G , Chandra, Sharat , Dorsey, Morna J , Cowan, Morton J , Dvorak, Christopher C , Haddad, Elie , Kohn, Donald B , Notarangelo, Luigi D , Puck, Jennifer M , Pulsipher, Michael A. , Torgerson, Troy R , Malech, Harry L , Kang, Elizabeth M , Parikh, Suhag , Leiding, Jennifer W , Shah, Ami J , Dara, Jasmeen , Cuvelier, Geoff D.E. , Chandrakasan, Shanmuganathan , Saldaña, Blachy J. Dávila , Broglie, Larisa , Ebens, Christen L. , DeSantes, Kenneth B , Moore, Theodore Bruce , Graham, Pamela, Dorsey, Morna J. , Haddad, Élie , Kohn, Donald B. , Malech, Harry L.
Blood | August 10, 2023 | Volume: 142 | Issue: 24 | Pages: 2105-2118
Abstract Chronic granulomatous disease (CGD) is a primary immunodeficiency characterized by life-threatening infections and inflammatory conditions. Hematopoietic cell transplantation (HCT) is the definitive treatment for CGD, but questions remain regarding patient selection and impact of active disease on transplant outcomes. We performed a multi-institutional retrospective and prospective study of 391 patients with CGD treated either conventionally (non-HCT) enrolled from 2004 to 2018 or with HCT from 1996 to 2018. Median follow-up after HCT was 3.7 years with a 3-year overall survival of 82% and event-free survival of 69%. In a multivariate analysis, a Lansky/Karnofsky score <90 and use of HLA-mismatched donors negatively affected survival. Age, genotype, and oxidase status did not affect outcomes. Before HCT, patients had higher infection density, higher frequency of noninfectious lung and liver diseases, and more steroid use than conventionally treated patients; however, these issues did not adversely affect HCT survival. Presence of pre-HCT inflammatory conditions was associated with chronic graft-versus-host disease. Graft failure or receipt of a second HCT occurred in 17.6% of the patients and was associated with melphalan-based conditioning and/or early mixed chimerism. At 3 to 5 years after HCT, patients had improved growth and nutrition, resolved infections and inflammatory disease, and lower rates of antimicrobial prophylaxis or corticosteroid use compared with both their baseline and those of conventionally treated patients. HCT leads to durable resolution of CGD symptoms and lowers the burden of the disease. Patients with active infection or inflammation are candidates for transplants; HCT should be considered before the development of comorbidities that could affect performance status. This trial was registered at www.clinicaltrials.gov as #NCT02082353.